Lake Street analyst Ben Haynor lowered the firm’s price target on Ekso Bionics (EKSO) to $2 from $2.50 and keeps a Buy rating on the shares. Despite the Q3 top line miss, Ekso is “doing well controlling expenses and international continued to gain traction during the quarter,” says the analyst, who cites an increased share count and slightly lower 2025 revenue forecast for the firm’s lowered price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EKSO:
- Ekso Bionics price target lowered to $9 from $10 at H.C. Wainwright
- Ekso Bionics reports Q3 EPS (10c), consensus (10c)
- EKSO Earnings this Week: How Will it Perform?
- Ekso Bionics prices $6M public offering at $1.00 per share
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
